Cargando…

2178. Resistance to Cefepime/Taniborbactam in NDM-1 -Are We Losing the Battle against MDROs?

BACKGROUND: Taniborbactam (TAN; Fig 1) is a novel cyclic boronate that inhibits Serine- and some Metallo-β-Lactamases like NDM and VIM. The combination cefepime (FEP)/ TAN has just completed a Phase III clinical trial. Notably, resistance mechanisms of FEP/TAN have already been described, such as th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ono, Daisuke, Mojica, Maria F, Bethel, Christopher R, Ishii, Yoshikazu, Moreno, Diego, Vila, Alejandro J, Bonomo, Robert A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678930/ http://dx.doi.org/10.1093/ofid/ofad500.1800

Ejemplares similares

1286. Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC)
por: Mack, Andrew R, et al.
Publicado: (2021)

133. ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam
por: Mack, Andrew R, et al.
Publicado: (2021)

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates
por: Le Terrier, Christophe, et al.
Publicado: (2023)

1063. ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam
por: Mack, Andrew R, et al.
Publicado: (2021)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

Losing battles /
por: Welty, Eudora, 1909-2001
Publicado: (1990)

Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States
por: Mojica, Maria F., et al.
Publicado: (2023)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

2185. In vitro activity of aztreonam-avibactam (ATM-AVI), cefiderocol (FDC), and cefepime-taniborbactam (FEP-TAN) against multi-species, NDM-producing Enterobacterales causing a local outbreak
por: Kline, Ellen G, et al.
Publicado: (2023)

The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli
por: Roach, Elyse J., et al.
Publicado: (2021)

865. Same Shift Susceptibility Testing of Cefepime-Taniborbactam and Cefiderocol Using The Selux Next-Generation Phenotyping System
por: Jimenez, David, et al.
Publicado: (2023)

1253. Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance
por: Hackel, Meredith, et al.
Publicado: (2021)

2129. Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates from the United States 2018-2021
por: Hackel, Meredith, et al.
Publicado: (2023)

2122. In Vitro Activity of Cefepime-Taniborbactam Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer
por: Gerges, Bahgat Z, et al.
Publicado: (2023)

Bronchopulmonary disposition of IV cefepime/taniborbactam (2–0.5 g) administered over 2 h in healthy adult subjects
por: Asempa, Tomefa E, et al.
Publicado: (2023)

A Situational Analysis of Antimicrobial Drug Resistance in Africa: Are We Losing the Battle?
por: Kimang'a, Andrew Nyerere
Publicado: (2012)

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
por: Hamrick, Jodie C., et al.
Publicado: (2020)

Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19
por: Golden, Alyssa R., et al.
Publicado: (2022)

Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern
por: Le Terrier, Christophe, et al.
Publicado: (2023)

The growing challenge of antimicrobial resistance in the South-East Asia Region - Are we losing the battle?
por: Bhatia, Rajesh, et al.
Publicado: (2010)

COVID-19: losing battles or winning the war?
por: Reperant, Leslie A., et al.
Publicado: (2020)

203. Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Pseudomonas aeruginosa from a Global 2018-2020 Surveillance Collection
por: Hackel, Meredith, et al.
Publicado: (2021)

Why We Will Continue to Lose Our Battle with Cancers If We Do Not Stop Their Triggers from Environmental Pollution
por: Cazzolla Gatti, Roberto
Publicado: (2021)

520. Development of Cefepime-taniborbactam MIC Antimicrobial Susceptibility Test (AST) for Enterobacterales and Pseudomonas aeruginosa on MicroScan Dried Gram-negative MIC Panels
por: Fernandez, Enrique J, et al.
Publicado: (2022)

2513. CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy in the Treatment of Complicated Urinary Tract Infections (cUTI)
por: Dorr, Mary Beth, et al.
Publicado: (2023)

Are we losing the battle against cardiometabolic disease? The case for a paradigm shift in primary prevention
por: Kraushaar, Lutz E, et al.
Publicado: (2009)

2178. Sensitivity of Blood Cultures in Detection of Bacteremia in Febrile Neutropenia
por: Patel, Vanisha, et al.
Publicado: (2019)

The Challenges of Underweight and Overweight in South African Children: Are We Winning or Losing the Battle? A Systematic Review
por: Monyeki, Makama Andries, et al.
Publicado: (2015)

2486. Winners and Losers: MDROs In The Time of COVID-19
por: Chan, Hwang Ching, et al.
Publicado: (2023)

Type 2 Diabetes: Why We Are Winning the Battle but Losing the War? 2015 Kelly West Award Lecture
por: Narayan, K.M. Venkat
Publicado: (2016)

731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
por: McGovern, Paul C, et al.
Publicado: (2022)

2178 Drug development core facilitates institutional collaboration and translational science innovation
por: Morse, Gene, et al.
Publicado: (2018)

Combating Sale of Counterfeit and Falsified Medicines Online: A Losing Battle
por: Lee, Kah Seng, et al.
Publicado: (2017)

Multidrug-resistant organisms (MDROs) in patients with subarachnoid hemorrhage (SAH)
por: Rhim, Ha-Young, et al.
Publicado: (2021)

2150. In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021
por: Wise, Mark G, et al.
Publicado: (2023)

2178. Detection of Key Potential Healthcare Pathogens Using Periodic Point Prevalence Surveillance
por: Schora, Donna, et al.
Publicado: (2018)

The effects of male age on sperm DNA damage: an evaluation of 2,178 semen samples
por: Petersen, Claudia G., et al.
Publicado: (2018)

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
por: Karlowsky, James A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bldtmf82gdoi9r80mt16t3lad4